Muscle Relaxant Drugs Market Size, Share, Growth, Trends | Report 2022-2030
The global muscle relaxant drugs market was estimated at USD 4.16 billion in 2021 and it is expected to surpass around USD 6.80 billion by 2030, poised to grow at a CAGR of 5.62% from 2022 to 2030.
The market is witnessing an increase in the use of relaxant drugs to treat muscle spasticity or spasms. This can be attributed due to the growing geriatric population with musculoskeletal disorders, the rising number of surgical procedures, sedentary lifestyle leading to back pain, work-related musculoskeletal disorders, and other factors leading to an increase in demand for such agents. For instance, according to an Elsevier article, a December 2021 research found that 64% of healthcare workers had a work-related musculoskeletal disease, with lower back pain being the most frequent complaint. Thus, the rising prevalence of such conditions is offering a lucrative opportunity for growth in the muscle relaxant drugs market.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 4.16 billion |
| Revenue Forecast by 2030 | USD 6.80 billion |
| Growth rate from 2022 to 2030 | CAGR of 5.62% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Drug Type, Distribution Channel, Region |
| Companies Covered |
Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Hikma Pharmaceuticals, Zydus Cadila, Ipsen Biopharmaceuticals Inc., Neurana Pharmaceuticals, Amneal Pharmaceuticals and others |
The market has been segmented by drug type:
The space has presence of a diverse group of medications in the management of condition. This includes three FDA-approved drugs baclofen, tizanidine, and dantrolene to treat spasticity, and six FDA-approved drugs carisoprodol, metaxalone, methocarbamol, chlorzoxazone, orphenadrine, and cyclobenzaprine indicated to treat muscular spasms. Botulinum toxin is another approved drug for spasticity but is used only for a certain group of cases.
Key market players are developing novel therapies and launching new products and generics in the muscle relaxant drugs market. For instance, in July 2021, Hikma Pharmaceuticals Plc. announced the launch of 20mg/ml Succinylcholine Chloride Injection indicated for skeletal muscle relaxation associated with surgery or mechanical ventilation in the U.S. Such neuromuscular blocking agents (example: succinylcholine, doxacurium, Cisatracurium, and rocuronium) are important during surgeries. In January 2022, Amneal Pharmaceuticals announced the successful acquisition of Saol's Baclofen franchise to enhance the company’s product portfolio with the Lioresal, Lyvispah, and clinical products in the segment.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Muscle Relaxant Drugs Market
5.1. COVID-19 Landscape: Muscle Relaxant Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Muscle Relaxant Drugs Market, By Drug Type
8.1. Muscle Relaxant Drugs Market, by Drug Type, 2022-2030
8.1.1. Facial Muscle Relaxants
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Skeletal Muscle Relaxants
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Neuromuscular Blocking Agents
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Muscle Relaxant Drugs Market, By Distribution Channel
9.1. Muscle Relaxant Drugs Market, by Distribution Channel, 2022-2030
9.1.1. Hospital pharmacies
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Retail pharmacies
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Others
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Muscle Relaxant Drugs Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Drug Type (2017-2030)
10.1.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Drug Type (2017-2030)
10.1.3.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
10.1.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Drug Type (2017-2030)
10.2.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Drug Type (2017-2030)
10.2.3.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
10.2.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
10.2.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Drug Type (2017-2030)
10.2.6.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Drug Type (2017-2030)
10.3.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Drug Type (2017-2030)
10.3.3.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
10.3.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
10.3.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Drug Type (2017-2030)
10.3.6.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
10.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Drug Type (2017-2030)
10.4.3.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
10.4.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
10.4.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Drug Type (2017-2030)
10.4.6.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
10.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Drug Type (2017-2030)
10.5.3.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
10.5.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 11. Company Profiles
11.1. Pfizer, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Teva Pharmaceuticals Industries Ltd.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Hikma Pharmaceuticals
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Zydus Cadila
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. LTE Scientific
11.5. Ipsen Biopharmaceuticals Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Neurana Pharmaceuticals
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Amneal Pharmaceuticals
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. others
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers